TG Therapeutics Inc (TGTX)

Financial leverage ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Total assets	US$ in thousands	586,014	401,207	373,323	329,587	331,067	220,854	197,358	193,572	217,891	251,666	303,028	379,629	409,687	481,400	548,699	625,642	273,856	294,621	101,849	163,014
Total stockholders’ equity	US$ in thousands	192,157	177,568	160,109	160,502	164,769	40,453	27,433	58,587	100,481	129,035	170,386	237,153	311,517	383,130	445,285	519,350	170,658	194,227	-1,353	38,615
Financial leverage ratio		3.05	2.26	2.33	2.05	2.01	5.46	7.19	3.30	2.17	1.95	1.78	1.60	1.32	1.26	1.23	1.20	1.60	1.52	—	4.22

September 30, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $586,014K ÷ $192,157K
= 3.05

The financial leverage ratio of TG Therapeutics Inc has fluctuated over time, indicating changes in the company's capital structure and debt levels. The ratio increased significantly from March 2022 to March 2023, reaching a peak of 7.19, which suggests higher financial risk and reliance on debt financing during that period.

However, from March 2023 to September 2024, the ratio decreased substantially, indicating a reduction in financial leverage and potentially a stronger equity position. The most recent ratio of 3.05 as of September 30, 2024, still suggests a moderate level of leverage compared to historical levels but is an improvement from the peak in March 2023.

Overall, monitoring TG Therapeutics Inc's financial leverage ratio over time can provide insights into the company's ability to meet its financial obligations and its risk exposure associated with its capital structure.